Navigation Links
Invest in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

.... Parshall. "In summary, it has been an eventful and promising first half of the year. Our financial position ensures that we can continue to invest our resources in filling the pipeline and continuing to move our drugs forward toward the market. We have the technology, the expertise and the momen...

First Potential Lupus-Specific Treatment in Sight

...ive and tolerable treatment for lupus, to the physicians who have passionately committed to researching this disease, to the companies who continue to invest in finding new treatments, and to the thousands of people with lupus who have volunteered and participated in clinical studies over the years so disco...

New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform

...ns know what works and are ready for government to invest in their health," said Senator Ron Wyden (D-OR). "...e-quarters of Americans believe the country should invest more in keeping people healthier, and by a nearly ...ly to keeping people healthy as the best reason to invest in prevention, with 72 percent agreeing with the s...

BIOCOM's 4th Annual DeviceFest Honors Companies

...categories (note: specific winners are listed): "I would invest in that" award (tied: OrthAlign and Applisonix ). "Why didn... "Life Changing" award ( Flexiciser ) The "I would invest in that" award was a tie between OrthAlign and Applisonix. OrthAlign exhib...

New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel

...- for some of the world's most urgent medical needs. This press release contains certain forward-looking statements about the potential of the invest i gational compound prasugrel (CS-747, LY640315) and reflects Daiichi Sankyo's and Lilly's cu r rent beliefs. However, as with any pharmaceutical...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

...is the furthest ahead in its clinical programs to bring a bioabsorbable drug eluting device to patients, and the company is committed to continuing to invest in this promising technology and to bring it to market as soon as possible." The ABSORB trial reinforces Abbott's commitment to research and dev...

Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments

...ained George F. Heinrich, M.D., vice chair and CEO of Foundation Venture Capital Group. Foundation Venture Capital Group was founded in 2006 to invest only in commercially viable new start-up companies developing technology at the University of Medicine & Dentistry of New Jersey . Since that tim...

ACRO Comments on NEJM Article on Globalization of Clinical Research

..., and ethical oversight of trials, which would allow them to engage more fully in multinational clinical research at a leadership level." ACRO members invest millions of dollars annually to recruit and train high-quality investigators in more than 60 countries. A well-trained, global investigator network is...

Breast Cancer Clinical Results Show Test Can Differentiate Normal, Early and Later Stage Cancers

...e, at least for a while," said Dr. Brent Norton, President and CEO of PreMD Inc. "We are hopeful that one or more interested parties' steps forward to invest in or acquire this technology as it has the potential to advance the fight against this disease," he added. About PreMD Inc. PreMD Inc. is a...

DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round

... investors, Blue Medical Investments and G1J-Ile de France, is committed to invest 2.2 million EUR based on certain milestones to be met. Since June 2008, DNA...investment strategy. Today, SGAM SEFTI has already invested, or is ready to invest in near term, more than half of the fund's commitments," said Beatrice Deny...

UK Must Maintain its Momentum in Stem Cell Expertise

...iginally founded ReNeuron in 1998 and has provided funding for the company over the last 10 years through Merlin 's Fund l and ll and has continued to invest in and support the company. Further information: Ramsay Smith, Media House, +44(0)207-397-8459, Email: ramsay@mediahouse.co.uk " target="_new">...

Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa

...rom the Bill & Melinda Gates Foundation to the PATH Malaria Vaccine Initiative. GSK has invested approximately $300 million to date and expects to invest another $50-100 million before the completion of the project. The clinical development of RTS,S/AS is led by the Clinical Trial Partnership Co...

Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand

...s of the $2 billion highly-niched, low-volume clinical and early-stage commercial sterile filling market segment. Pharmaceutical companies can invest over $100 million and four years to develop sterile manufacturing capacity, but are highly reluctant to take this initiative until they are certain th...

Isogen Launches Major New Facility to Address Global Biopharma Demand

...nly associated with the $2 billion highly-niched, low-volume clinical and early-stage commercial sterile filling market segment. Companies can invest over $100 million and four years to develop sterile manufacturing capacity, but are highly reluctant to take this initiative until they are certain th...

Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test

...RL will put in place intensive and extensive market-facing strategies to ensure rapid growth in the market, both locally and internationally, and will invest substantial amounts and efforts to inform the market on the availability of this new innovative test." Corporate Inquiries Erik Christensen, Man...

CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine

...s on the areas of head and neck cancer, nasopharyngeal cancer and potentially cervical cancer. As part of this new agreement, Orient Europharma will invest $500,000 in CEL-SCI and fund a portion of the Company's global Phase III clinical trial for Multikine due to start in 2009. Orient Europharma's clinic...

Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio

...g new positions. With a broad development program including 6 ongoing Phase III studies, we must prioritize spending to ensure that we can continue to invest effectively for the future." Conference Call Genmab will hold a conference call to discuss the outcome of the portfolio review today, October 8, 200...

Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting

...lf CJ, Hashmi M. Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids. Curr Opin invest Drugs. 2004; 5:61-66. 4. Gagnon AM, Kahan M, Srivastava A. Opioid use and abuse: is there a problem? Clin J Pain. 2007; 23:661-662. 5. Birnbaum HG...

New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option

... together to ensure that these studies are supported to produce the data needed to determine next steps on the possible use of PrEP. 2. Identify and invest in additional research: A plan for launching additional studies - including studies on the safety and efficacy on intermittent PrEP dosing, bridging s...

Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City

...123(R) non-cash stock-based compensation expense in the range of $19 to $23 million remain unchanged. "We have consistently managed our resources to invest into the growth of our pipeline," said Christian S. Schade, Senior Vice President and CFO of Medarex. "Our commitment to steadily support our research...

Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies

...nzymatic processes associated with early stage cancer development in vivo. In addition to conducting the clinical trials, Fox Chase Cancer Center will invest in the ProSense clinical program through VisEn and will receive certain rights, equity and royalties on future sales. "These clinical molecular imag...

Grocery Manufacturers Association: Study Signals Progress in Battle Against Obesity

...ll stakeholders in this critically important effort. We will continue to provide consumers with healthier options, market our products responsibly and invest in programs that promote healthy eating and more physical activity." The Grocery Manufacturers Association (GMA) represents the world's leading food...

Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session

...lf CJ, Hashmi M. Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids. Curr Opin invest Drugs. 2004;5:61-66. 4. Gagnon AM, Kahan M, Srivastava A. Opioid use and abuse: is there a problem? Clin J Pain. 2007;23:661-662. 5. Birnbaum HG, ...

Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation

...anuscripts an analysis of how the subject population's demographics correspond to those of the population that bears the greatest disease burden. 5. invest in specialized training for Institutional Review Boards. Although the mission of institutional review boards (IRBs) is to safeguard the rights, safety...

Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population

...death worldwide. Boehringer Ingelheim has introduced novel agents in the management of hypertension and treatment of secondary stroke and continues to invest in a comprehensive cardiovascular pipeline. The Company's cardiovascular medicine clinical trial program includes ONTARGET, PRoFESS, TRANSCEND and oth...

Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study

...the efficacy of Medifast Meal Replacements in the clinical setting," said Brad MacDonald, Chairman of the Board, Medifast, Inc. "Medifast continues to invest in the research and development of its products and programs to ensure that our claims to consumers are the most documented and credible in the indust...

EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers

...rway to test the safety and efficacy of MKC- 1 in solid and hematological cancers, including two clinical development programs in Canada. We expect to invest in further clinical trials during 2008 to test the extent of MKC-1's clinical utility in multiple tumor types." About Ovarian and Endometrial Cancer...

GSK Does Not Option XL784 for Further Development

...d appear to show a substantial benefit from XL784, although this difference did not reach statistical significance. Exelixis itself does not intend to invest further in the development of this drug, but will seek a partner with which to take the compound forward. XL784 is part of Exelixis' clinical develo...

Survey Finds U.S. Healthcare Facilities Not Doing Enough to Curb MRSA

... Consumers Union Calls on Hospitals to invest More Resources and Take Aggressive Steps to Prevent MRSA Infections WASHINGTON, Dec. 11 /PRNewswire-USNewswire/ -- U.S. healthcare facilities aren...

Your Hearing May be at Risk, Says Harvard Men's Health Watch

...rovides some sound advice: First and foremost, turn down the volume. For occasional exposures, use disposable ear plugs. If you're frequently at risk, invest in custom-fitted ear plugs. And for maximum protection, add acoustic earmuffs. Also in this issue: -- Gout: Joint pain and more -- Supplements vs....

Mitchell, Military TBI Task Force Highlight the Importance of Traumatic Brain Injury Research; Mitchell Endorses Ground Breaking Traumatic Brain Injury Study

...nging more of our troops home alive, but they are suffering from combat-related TBI or PTSD in greater numbers than in past wars. We owe it to them to invest in this kind of research that will help improve their quality of life in the years to come." Earlier this year, Mitchell voted for and the House pas...

Facet Solutions' AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing

...esigned with the objective of overcoming the inherent weaknesses of spinal fusion and dynamic stabilization. As a company, we felt it was important to invest in this stringent testing procedure to ensure that the AFRS(TM) would result in positive clinical outcomes. We were pleased to find that our product o...

Atritech Announces Completion of a $22 Million Equity Financing

...ttp://www.atritech.net . About SightLine Partners SightLine Partners LLC is a Minneapolis, MN based venture firm that manages a series of funds that invest in promising emerging growth companies in the medical device industry. For more information, visit http://www.sightlinepartners.com . ...

WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals' CEO

...l as for other functions critical to its mission and enhances RegeneRx's ability to allocate resources rapidly to different projects without having to invest in infrastructure. For more information about this Company, please visit http://www.regenerx.com . About WallSt.net: http://www.wallst.net is ow...

Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's Conference

...aste: Emerging Trends for Alzheimer's Disease." The invitation only event for institutional investors, venture capitalists and hedge fund managers who invest in the healthcare sector, highlights select companies developing Alzheimer's treatments. "Our Alzheimer's program is based on this very compelling d...

MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia

...xperience in autologous cell processing that corresponds to treatment for over 6,000 cancer patients in actual clinical practice. Medinet continues to invest in R&D to improve cell processing technologies in an effort to increase efficacy in collaborative clinical studies with university hospitals and m...
Other Tags
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
(Date:10/16/2014)... wages war on the human body. Battles are ... In pancreatic cancer, this stalemate—known as tumor dormancy—can ... malignant, a phenomena that is poorly understood. ... laboratory of Salvatore Torquato, a Professor of Chemistry ... surrounding tumor dormancy and the switch to a ...
(Date:10/16/2014)... cultivated efficiently, they are anything but sustainable: environmental ... cultivation is becoming increasingly evident. Despite their disadvantages, ... are regarded as the sole possibility of achieving ... finds Bernhard Schmid, an ecology professor at the ... of agriculture and forestry. After all, a new ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Losing Weight Your ... industry is staring you in the face, it certainly can ... not do your body an extra favor by doing it ... tempting crash diets. Instead, listen to your body, exercise regularly, ... Exercise is essential to losing weight; you need to exercise ...
(Date:10/22/2014)... 2014 Lintelus, Inc., an event software ... of Sales, will be speaking on the subject of ... on October 28, at the Holiday Inn in New ... as well as a Tech Demo at 12:45pm, to ... a more engaging event experience. , The Annual Meetings ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... women undergoing in vitro fertilization (IVF) are only about half ... popular assisted reproduction technique, new research indicates, and the racial ... the study, about 31 percent of white patients became pregnant ... Analyzing more than 4,000 IVF cycles over two years ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
Other Contents